Mycoplasma in Poultry: Causes, Clinical Signs in Chicken Poop, and Control Strategies

Introduction

Mycoplasma infections in poultry represent a significant economic burden to the global poultry industry. The two primary pathogenic species are Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS). These cell wall-deficient bacteria cause chronic respiratory disease (CRD) in chickens and turkeys, leading to reduced egg production, decreased feed conversion efficiency, increased mortality, and carcass condemnation at processing. Unlike many bacterial pathogens, mycoplasmas lack a rigid peptidoglycan cell wall, rendering them intrinsically resistant to beta-lactam antibiotics and conferring unique diagnostic and therapeutic challenges. This article provides an exhaustive review of the causes, clinical manifestations including fecal alterations, and evidence-based control strategies for mycoplasmosis in poultry.

Etiology and Taxonomy

Mycoplasmas belong to the class Mollicutes, order Mycoplasmatales, and family Mycoplasmataceae. They are the smallest self-replicating prokaryotes, with genome sizes ranging from 580 to 1350 kilobase pairs. The absence of a cell wall is a defining characteristic that influences their pleomorphic morphology, osmotic fragility, and antibiotic susceptibility profile.

Mycoplasma gallisepticum is the most economically significant species. It is the primary etiological agent of CRD in chickens and infectious sinusitis in turkeys. Mycoplasma synoviae causes subclinical respiratory infections and infectious synovitis, characterized by joint inflammation and lameness. Other species such as M. meleagridis and M. iowae are relevant in turkeys but are less prevalent in commercial chicken flocks.

Causes and Predisposing Factors

The causes of mycoplasma in poultry are multifactorial, involving pathogen introduction, host susceptibility, and environmental stressors.

Primary Causes

1. Introduction of Infected Birds: The most common route of introduction into a naive flock is through the addition of laterally infected replacement stock or breeder birds. Vertical transmission via the egg is a critical mechanism for MG and MS, allowing the pathogen to persist across generations.
2. Horizontal Transmission: Direct bird-to-bird contact through respiratory aerosols, contaminated feed, water, and fomites facilitates rapid spread within a flock. Dust and feathers in poultry houses can harbor viable mycoplasmas for extended periods.
3. Persistent Environmental Contamination: Mycoplasmas can survive in organic material, litter, and water for days to weeks, depending on temperature and humidity. They are susceptible to desiccation and direct sunlight but can persist in cool, moist environments.

Predisposing Factors

Several factors increase the severity and incidence of clinical disease:

• Concurrent Viral or Bacterial Infections: Co-infection with Newcastle disease virus, infectious bronchitis virus, or Escherichia coli (as discussed in Escherichia coli in Chickens and Poultry Products) exacerbates the pathogenicity of MG. The immunosuppressive effects of these agents allow mycoplasmas to proliferate unchecked.
• Environmental Stressors: High stocking density, poor ventilation leading to elevated ammonia levels, temperature fluctuations, and nutritional deficiencies compromise mucosal immunity and facilitate mycoplasma colonization.
• Vaccination Stress: Live virus vaccines, particularly those administered via coarse spray, can induce transient respiratory inflammation that predisposes birds to secondary mycoplasma infection.
• Age and Immune Status: Young birds are more susceptible to severe disease. Maternal antibodies provide partial protection but wane within the first few weeks of life.

Pathogenesis and Host-Pathogen Interactions

Mycoplasmas colonize the mucosal surfaces of the respiratory tract, primarily the trachea, air sacs, and sinuses. M. synoviae also has a tropism for synovial membranes and joint capsules. The pathogenesis involves several key mechanisms:

1. Adhesion: Mycoplasmas adhere to host epithelial cells via specialized adhesin proteins, such as GapA and CrmA in MG. This adhesion is essential for colonization and prevents mucociliary clearance.
2. Cytotoxicity and Inflammation: The bacteria produce hydrogen peroxide and superoxide radicals, which damage host cell membranes. Lipoproteins and membrane components trigger a robust inflammatory response characterized by infiltration of lymphocytes, macrophages, and heterophils.
3. Immune Evasion: Mycoplasmas exhibit high antigenic variation through phase and size variation of surface lipoproteins. This allows them to evade the host immune response and establish chronic, persistent infections.
4. Immunopathology: Much of the tissue damage in CRD is due to the host's own immune response. The formation of lymphoid follicles and hyperplasia of mucosal-associated lymphoid tissue leads to airway obstruction and airsacculitis.

Clinical Signs in Chickens

The clinical presentation of mycoplasmosis varies depending on the species involved, the age of the bird, and the presence of concurrent infections.

Respiratory Signs (MG and MS)

• Nasal Discharge: Serous to mucopurulent exudate from the nares.
• Sinusitis: Swelling of the infraorbital sinuses, particularly in turkeys.
• Coughing and Sneezing: Frequent, paroxysmal coughing and sneezing.
• Tracheal Rales: Audible rattling sounds upon auscultation, indicative of tracheal exudate.
• Dyspnea: Labored breathing, open-mouth breathing, and extension of the neck.
• Conjunctivitis: Ocular discharge and periorbital swelling.

Non-Respiratory Signs

• Reduced Feed and Water Intake: Anorexia is common in acute cases.
• Decreased Egg Production: A drop of 10-30% in laying hens is typical. Eggshell quality may also decline.
• Lameness and Joint Swelling: Characteristic of M. synoviae infection. Birds may be reluctant to move and exhibit a stilted gait.
• Stunting and Poor Growth: In broilers, chronic infection leads to uneven growth and increased culling rates.

Mycoplasma Chicken Poop: Clinical Signs in Feces

The term "mycoplasma chicken poop" refers to fecal changes that are secondary to the systemic effects of infection rather than direct enteric pathology. Mycoplasmas do not typically cause primary enteritis. However, the clinical signs in chicken poop observed during mycoplasmosis include:

• Greenish, Watery Diarrhea: This is a common finding in birds with severe respiratory distress and anorexia. The green coloration results from the excretion of biliverdin, a bile pigment that accumulates when the bird is not eating. The watery consistency reflects increased water intake (polydipsia) secondary to fever and respiratory fluid loss.
• Undigested Feed Particles: In chronic cases, malabsorption due to reduced feed intake and altered gut motility may result in feces containing recognizable feed particles.
• Mucus in Feces: While not a hallmark of mycoplasmosis, stress-induced enteritis or concurrent coccidiosis (see What Causes Coccidiosis in Chickens) can lead to increased mucus production.
• Urate Staining: White, chalky urates may be more prominent in dehydrated birds.

It is critical to differentiate these fecal changes from those caused by primary enteric pathogens such as Salmonella (see Salmonella in Chickens), Clostridium perfringens (see Necrotic Enteritis in Broiler Chickens), or coccidia. Fecal examination alone is insufficient for diagnosing mycoplasmosis.

Diagnostic Approaches

Accurate diagnosis is essential for implementing effective control measures. A combination of clinical observation, serology, and molecular detection is recommended.

Clinical and Postmortem Examination

• Gross Lesions: Airsacculitis (cloudy, thickened air sacs with caseous exudate), tracheitis, and peritonitis. In MS cases, synovitis with viscous, yellowish joint fluid is observed.
• Histopathology: Lymphoid hyperplasia, mucosal thickening, and heterophilic infiltration in the trachea and air sacs.

Serological Testing

• Rapid Serum Agglutination (RSA) Test: A simple, inexpensive screening test using stained antigen. It is sensitive but can yield false positives due to cross-reactivity with other mycoplasma species or non-specific agglutinins.
• Enzyme-Linked Immunosorbent Assay (ELISA): Commercial ELISA kits are widely used for flock-level surveillance. They offer higher specificity and can differentiate between MG and MS. The principles of ELISA are analogous to those described for Feline Leukemia Virus antigen detection, though the target here is antibody.
• Hemagglutination Inhibition (HI) Test: A more specific serological test used for confirmatory diagnosis and strain typing.

Molecular Detection

• Polymerase Chain Reaction (PCR): PCR targeting species-specific genes (e.g., the mgc2 gene for MG, the vlhA gene for MS) is the gold standard for direct detection. It offers high sensitivity and specificity and can differentiate between MG and MS in a single reaction. Real-time PCR (qPCR) allows for quantification of bacterial load.
• DNA Sequencing: Sequencing of PCR amplicons can provide epidemiological information and identify emerging strains.

Culture

• Isolation: Mycoplasmas require specialized media (e.g., Frey's medium) and are slow-growing, taking 3-10 days. Culture is labor-intensive and less sensitive than PCR but remains important for antimicrobial susceptibility testing.

Control Strategies

Control of mycoplasmosis relies on a combination of biosecurity, management, vaccination, and antimicrobial therapy.

Biosecurity and Management

• All-In/All-Out Production: Complete depopulation and cleaning of facilities between flocks breaks the cycle of infection.
• Source Control: Procuring birds from certified mycoplasma-free breeder flocks is the most effective preventive measure.
• Quarantine: New birds should be quarantined for a minimum of 30 days and tested before introduction.
• Ventilation and Litter Management: Maintaining low ammonia levels and dry litter reduces respiratory irritation and pathogen survival.
• Rodent and Pest Control: Rodents can act as mechanical vectors for mycoplasmas.

Vaccination

• Live Vaccines: Attenuated live vaccines (e.g., the F strain and ts-11 strain for MG) are administered via eye drop or coarse spray. They induce local and systemic immunity but can cause mild reactions and may revert to virulence.
• Inactivated Vaccines: Bacterins are used primarily in breeder flocks to boost maternal antibody levels. They are safer than live vaccines but provide less robust mucosal immunity.
• Recombinant Vaccines: Vector vaccines using fowlpox virus or E. coli expressing MG antigens are under development.

Antimicrobial Therapy

Treatment is aimed at reducing clinical signs and transmission but does not eliminate the organism from the flock. The choice of antibiotic is guided by the lack of a cell wall.

Antimicrobial Resistance: Resistance to macrolides and tetracyclines has been reported globally. Susceptibility testing via broth microdilution is recommended to guide therapy.

Eradication Programs

In many commercial breeding operations, eradication is the ultimate goal. This involves:

1. Testing and Removal: Serological and PCR testing of all birds in a flock, followed by culling of positive individuals.
2. Medication of Breeders: In-feed or in-water antibiotics to reduce vertical transmission.
3. Egg Treatment: Dipping eggs in an antibiotic solution (e.g., tylosin or gentamicin) or heat treatment to eliminate mycoplasmas from the egg surface.
4. Replacement with Clean Stock: Repopulating with mycoplasma-free birds.

Diagnostic and Control Decision Workflow

The following Mermaid diagram illustrates a systematic approach to managing a suspected mycoplasma outbreak.

flowchart TD
    A[Clinical Signs: Respiratory distress, drop in egg production, lameness], > B{Examine feces}
    B, > C[Green, watery diarrhea with urates]
    B, > D[Normal feces or other abnormalities]
    C, > E[Consider systemic infection: Mycoplasma, viral, or bacterial]
    D, > F[Rule out primary enteric pathogens]
    E, > G[Collect samples: Tracheal swabs, serum, joint fluid]
    G, > H{Diagnostic Testing}
    H, > I[Serology: RSA or ELISA]
    H, > J[Molecular: PCR for MG/MS]
    H, > K[Culture and sensitivity]
    I, > L[Positive serology]
    J, > M[Positive PCR]
    K, > N[Isolate and AST]
    L & M, > O[Confirm Mycoplasma infection]
    O, > P{Control Strategy}
    P, > Q[Biosecurity: Quarantine, all-in/all-out]
    P, > R[Vaccination: Live or inactivated]
    P, > S[Antimicrobial therapy: Tiamulin, Tylosin]
    P, > T[Eradication: Test and cull, egg treatment]
    S, > U[Monitor clinical response and resistance]
    T, > V[Repopulate with certified free stock]

Differential Diagnoses

Mycoplasmosis must be differentiated from other respiratory and systemic diseases of poultry.

• Infectious Coryza: Caused by Avibacterium paragallinarum (see Infectious Coryza in Chickens and Quail). Presents with facial swelling and nasal discharge but lacks airsacculitis.
• Fowl Cholera: Caused by Pasteurella multocida (see Fowl Cholera in Poultry). Acute septicemia with high mortality and characteristic liver lesions.
• Avian Influenza and Newcastle Disease: Viral causes of severe respiratory and systemic disease. Requires molecular testing for differentiation.
• Aspergillosis: Fungal infection causing respiratory distress, often with gasping and greenish diarrhea. Characterized by granulomatous lesions in the lungs and air sacs.
• Colibacillosis: Secondary E. coli infection often complicates mycoplasmosis. Airsacculitis and pericarditis are common.

Conclusion

Mycoplasma gallisepticum and M. synoviae remain formidable pathogens in commercial poultry production. The causes of mycoplasma in poultry are rooted in vertical transmission, horizontal spread, and environmental persistence. Clinical signs, including the characteristic greenish, watery mycoplasma chicken poop, are secondary to systemic illness and respiratory distress rather than direct enteric infection. Effective control requires a multifaceted approach combining rigorous biosecurity, strategic vaccination, judicious antimicrobial use guided by susceptibility testing, and, where feasible, eradication programs. Advances in molecular diagnostics, particularly real-time PCR, have greatly enhanced the ability to detect and differentiate these pathogens rapidly. Continued surveillance for antimicrobial resistance and the development of improved vaccines are essential for sustainable management.

References

1. Kleven, S. H. (2008). Control of avian mycoplasma infections in commercial poultry. Avian Diseases, 52(3), 367-374.
2. Ley, D. H., & Yoder, H. W. (1997). Mycoplasma gallisepticum infection. In Diseases of Poultry (10th ed., pp. 194-207). Iowa State University Press.
3. Bradbury, J. M. (2005). Avian mycoplasmas. In Poultry Diseases (6th ed., pp. 178-193). Elsevier.
4. Ferguson-Noel, N., & Williams, S. M. (2015). The efficacy of Mycoplasma gallisepticum vaccines in commercial layers. Avian Pathology, 44(5), 375-380.
5. Ghanem, M., & El-Gazzar, M. (2018). Development of a real-time PCR assay for the detection and differentiation of Mycoplasma gallisepticum and Mycoplasma synoviae. Journal of Veterinary Diagnostic Investigation, 30(4), 567-573.
6. World Organisation for Animal Health (WOAH). (2021). Avian Mycoplasmosis (Mycoplasma gallisepticum, M. synoviae). In Manual of Diagnostic Tests and Vaccines for Terrestrial Animals.